- Home
- SNT vs FBIO Comparison
SNT vs FBIO Comparison
Compare SNT & FBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNT
- FBIO
- Stock Information
- Founded
- SNT 1965
- FBIO 2006
- Country
- SNT Canada
- FBIO United States
- Employees
- SNT N/A
- FBIO N/A
- Industry
- SNT Telecommunications Equipment
- FBIO Biotechnology: Pharmaceutical Preparations
- Sector
- SNT Telecommunications
- FBIO Health Care
- Exchange
- SNT Nasdaq
- FBIO Nasdaq
- Market Cap
- SNT 95.2M
- FBIO 88.7M
- IPO Year
- SNT 1993
- FBIO N/A
- Fundamental
- Price
- SNT $4.93
- FBIO $2.56
- Analyst Decision
- SNT
- FBIO Strong Buy
- Analyst Count
- SNT 0
- FBIO 2
- Target Price
- SNT N/A
- FBIO $16.50
- AVG Volume (30 Days)
- SNT 64.1K
- FBIO 1.2M
- Earning Date
- SNT 11-11-2025
- FBIO 11-13-2025
- Dividend Yield
- SNT N/A
- FBIO N/A
- EPS Growth
- SNT N/A
- FBIO N/A
- EPS
- SNT 0.22
- FBIO N/A
- Revenue
- SNT $38,038,000.00
- FBIO $59,301,000.00
- Revenue This Year
- SNT N/A
- FBIO $31.85
- Revenue Next Year
- SNT N/A
- FBIO $44.43
- P/E Ratio
- SNT $22.09
- FBIO N/A
- Revenue Growth
- SNT 12.79
- FBIO N/A
- 52 Week Low
- SNT $1.40
- FBIO $1.33
- 52 Week High
- SNT $5.34
- FBIO $4.20
- Technical
- Relative Strength Index (RSI)
- SNT 56.41
- FBIO 39.06
- Support Level
- SNT $4.33
- FBIO $2.47
- Resistance Level
- SNT $5.34
- FBIO $2.61
- Average True Range (ATR)
- SNT 0.32
- FBIO 0.14
- MACD
- SNT 0.03
- FBIO -0.05
- Stochastic Oscillator
- SNT 62.85
- FBIO 22.09
About SNT Senstar Technologies Ltd.
Senstar Technologies Corp is a provider of comprehensive physical, video, and access control security products and solutions. Its perimeter intrusion detection systems (including fence sensors, buried sensors, and above-ground sensors), intelligent video management, video analytics, and access control offer a comprehensive suite of integrated solutions that reduce complexity, improve performance, and unify support.
About FBIO Fortress Biotech Inc.
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology and therapeutics sectors.